ABX464: Clinical Trials

5 trials of ABX464, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 5 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 2, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 22Terminated 1, Withdrawn 1

Follow ABX464: new trials by email Literature Review of ABX464 trials Research Report on ABX464

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
ABX464, Placebo - Ulcerative Colitis
Phase 3CompletedAbivax S.A.6362023-01-252026-09-10
ABTECT - Maintenance
ABX464, Placebo - Ulcerative Colitis
Phase 3Active not recruitingAbivax S.A.11162023-01-162026-07-07
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
ABX464, Placebo - Ulcerative Colitis
Phase 3CompletedAbivax S.A.6392022-11-162026-09-10
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
ABX464, Placebo - Crohn Disease
Phase 2 / Phase 3WithdrawnAbivax S.A.2022-09-192024-07-31
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
ABX464, Placebo - COVID-19
Phase 2 / Phase 3TerminatedAbivax S.A.5092020-07-012025-11-26

Conditions studied

Colitis, Ulcerative (3)  ·  COVID-19 (1)  ·  Crohn Disease (1)

Sponsors

Abivax S.A. (5)

Countries

Belgium (5)  ·  France (4)  ·  Germany (4)  ·  Italy (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Argentina (3)  ·  Brazil (3)  ·  Bulgaria (3)  ·  Canada (3)  ·  Czechia (3)  ·  Hungary (3)  ·  India (3)  ·  Mexico (3)  ·  Poland (3)

Top investigators

Bruce Sands, MD, PhD (3)  ·  Severine Vermeire, MD, PhD (3)